X-150659654-A-G
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM2PP3PP5_Very_Strong
The NM_000252.3(MTM1):c.1261-10A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000184 in 1,084,198 control chromosomes in the GnomAD database, with no homozygous occurrence. There are no hemizygote samples in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000252.3 intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MTM1 | NM_000252.3 | c.1261-10A>G | intron_variant | Intron 11 of 14 | ENST00000370396.7 | NP_000243.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome AF: 0.00000184 AC: 2AN: 1084198Hom.: 0 Cov.: 27 AF XY: 0.00 AC XY: 0AN XY: 350926
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
Severe X-linked myotubular myopathy Pathogenic:10Other:1
This variant represents a recurrent intronic alteration that has been previously reported as a hemizygous change in several males affected with X-linked myotubular myopathy (PMID: 9285787, 20358311, 10502779, 15725586, 9450905). In several of the reported individuals a diagnosis of myotubular myopathy was confirmed on muscle biopsy (PMID: 9285787, 20358311). This variant is also known as IVS12-10A>G and A(1315-10)G in the literature. It is absent from the gnomAD population database and thus is presumed to be rare. Multiple splice prediction tools suggest that this variant is likely to interfere with normal splicing. Splicing studies have shown that this variant creates a new acceptor splice site leading to the inclusion of nine nucleotides of intron 11 (PMID: 9450905, 9285787). Based on the available evidence, the c.1261-10A>G variant is classified as Pathogenic. -
- -
- -
This sequence change falls in intron 11 of the MTM1 gene. It does not directly change the encoded amino acid sequence of the MTM1 protein. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individuals with myotubular myopathy (PMID: 9285787, 9450905, 10502779, 15725586, 20358311). It has also been observed to segregate with disease in related individuals. This variant is also known as IVS12-10A>G and A(1315-10)G. ClinVar contains an entry for this variant (Variation ID: 11058). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
- -
- -
- -
PM2, PP3, PP5 -
- -
Variant summary: MTM1 c.1261-10A>G alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: Two predict that the variant creates a new 3-prime acceptor site. These predictions have been corroborated by several publications reporting experimental evidence that this variant affects mRNA splicing (e.g. deGouyon_1997, Nishino_1998). The variant was absent in 183100 control chromosomes. c.1261-10A>G has been reported in the literature in multiple individuals affected with Severe X-Linked Myotubular Myopathy (e.g.deGouyon_1997, Nishino_1998, Bijarnia_2010). These data indicate that the variant is very likely to be associated with disease. Three other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories cited the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
- -
not provided Pathogenic:2
- -
Published functional studies show that c.1261-10 A>G results in reduced MTM1 mRNA expression and absent MTM1 protein on Western blot of a patient muscle biopsy (Falcone et al., 2014); Published RNA studies show that this variant creates a new acceptor splice site that results in the addition of three amino acids to the transcript (de Gouyon et al., 1997); Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 10063835, 15725586, 34440373, 28685322, 31395954, 10790201, 9829274, 12522554, 9305655, 10502779, 10323249, 11793470, 9285787, 20358311, 27017278, 27600705, 33164942, 25262827) -
Centronuclear myopathy Pathogenic:1
PS3+PS4+PM1+PM2+PP3+PP5 -
MTM1-related disorder Pathogenic:1
The MTM1 c.1261-10A>G variant is predicted to interfere with splicing. This variant has been reported in several male patients with X-linked myotubular myopathy (reported as IVS12-10A>G in de Gouyon et al 1997. PubMed ID: 9285787; Tsai et al. 2005. PubMed ID: 15725586; Bijarnia et al. 2010. PubMed ID: 20358311; Laporte. 2000. PubMed ID: 10790201; Table S1, Biancalana et al. 2017. PubMed ID: 28685322; Gangfuss et al. 2021. PubMed ID: 33164942). This variant was also reported in at least one female carrier who presented with muscle weakness, pseudo-bulbar symptoms, and skeletal joints related issues (Table S1, Biancalana et al. 2017. PubMed ID: 28685322). RNA studies support that the c.1261-10A>G variant affects RNA spicing (de Gouyon et al 1997. PubMed ID: 9285787, see Figure 2). This variant has not been reported in a large population database, indicating this variant is rare. This variant is interpreted as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at